Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Journey Medical (DERM) EBITDA: 2020-2024

Historic EBITDA for Journey Medical (DERM) over the last 5 years, with Dec 2024 value amounting to -$13.7 million.

  • Journey Medical's EBITDA rose 47.17% to -$1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.5 million, marking a year-over-year increase of 69.50%. This contributed to the annual value of -$13.7 million for FY2024, which is 559.77% down from last year.
  • Per Journey Medical's latest filing, its EBITDA stood at -$13.7 million for FY2024, which was down 559.77% from -$2.1 million recorded in FY2023.
  • Journey Medical's 5-year EBITDA high stood at $7.9 million for FY2020, and its period low was -$34.9 million during FY2021.
  • Over the past 3 years, Journey Medical's median EBITDA value was -$13.7 million (recorded in 2024), while the average stood at -$14.4 million.
  • In the last 5 years, Journey Medical's EBITDA soared by 92.47% in 2023 and then slumped by 559.77% in 2024.
  • Journey Medical's EBITDA (Yearly) stood at $7.9 million in 2020, then plummeted by 544.29% to -$34.9 million in 2021, then climbed by 21.11% to -$27.5 million in 2022, then spiked by 92.47% to -$2.1 million in 2023, then tumbled by 559.77% to -$13.7 million in 2024.